Drug intelligence / Profile preview

Bifidobacterium brevis CCFM1078

Development stage: Preclinical
Lead developer: Jiangnan University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium brevis CCFM1078 is a specific probiotic strain of the species *Bifidobacterium brevis*. It is currently being evaluated in clinical trials, such as ChiCTR2400094620, for its efficacy and safety in treating acute diarrhea in infants. The strain is often studied in combination with other probiotics like *Bifidobacterium longum* CCFM1269. Its mechanism involves modulating the intestinal microbiota and metabolome to restore gut health and potentially reduce the duration of diarrheal symptoms. The research is primarily led by the Department of Gastroenterology at the Children's Hospital of Shanghai.

Other names: B. brevis CCFM1078

Beyond the preview

Go deeper on Bifidobacterium brevis CCFM1078.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium brevis CCFM1078.

Explore the full profile